Pryor Cashman advised client Miltenyi Biotec GmbH, a German biotech company, on its acquisition of the lentiviral vector manufacturing business and related assets from U.S. company Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications.

The assets acquired in this transaction include a wide range of intellectual property, process technologies and cGMP-qualified manufacturing facilities in Gaithersburg, Maryland and will further strengthen Miltenyi Biotec’s portfolio in cell and gene therapy. The Lentigen team will join Miltenyi Biotec, and operate through its newly formed, wholly owned U.S. subsidiary Lentigen Technology, Inc.

The Pryor Cashman team representing Miltenyi Biotec was comprised of Corporate Partner Juergen Ostertag and Associates Lloyd Steele, Durre Hanif and Nir Gozal, with assistance from Partner Jeffrey Johnson of Pryor Cashman’s Intellectual Property Group, and Associate Ari Tran of the Real Estate Group.